Compare Recursion Pharmaceuticals Inc (RXRX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Spotify Technology — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Spotify Technology trades at $492.88 (market cap $101.23B). The key difference: Spotify Technology is far larger — about 66.2× Recursion Pharmaceuticals Inc's market cap, and Spotify Technology is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPOT | |
|---|---|---|
Market Cap | $1.53B | $101.23B |
Sector | Health | Media |
52-Week High | $6.79 | $738.53 |
52-Week Low | $2.84 | $412.75 |
Enterprise Value | $946.50M | $91.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Spotify (SPOT) trades at $493.23, up 3.16% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $481 and resistance at $500. Fundamentally, revenue grew to $17.19B in 2025 with net income surging to $2.21B, reflecting improved profitability. Recent developments include AI feature expansions and parent-managed accounts for free users, enhancing growth prospects.
Outlook remains positive with analyst consensus target at $617, though rich valuation (P/E 33.54) and competition pose risks. Earnings growth and AI integration present opportunities, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
